NCT05432804 2026-03-18
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Suspended
Clinical Trials
7 trialsNCT05642195 2026-03-18
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT06219174 2026-03-06
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Suspended
NCT06232044 2026-03-04
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Suspended
NCT06085729 2026-02-27
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Phase 1/2 Suspended
NCT05419479 2026-02-24
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Phase 1/2 Suspended
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended